Drug Profile


Alternative Names: CGP 37391; CMX 001 - CorMedix; CP 020; CP 20; CRMD-001; Ferriprox; Ferriprox Oral Solution; Kelfer; L1

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Royal Free and University College Medical School
  • Developer Apotex; Centre Hospitalier Univeristaire De Lille; CorMedix
  • Class Antianaemics; Antineoplastics; Antirheumatics; Pyridones; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron overload
  • Phase III Pantothenate kinase-associated neurodegeneration
  • Phase II Amyotrophic lateral sclerosis; Parkinson's disease
  • Phase I HIV infections
  • No development reported Friedreich's ataxia
  • Discontinued Kidney disorders

Most Recent Events

  • 11 Jan 2017 ApoPharma completes a phase III trial in Pantothenate Kinase Associated Neurodegeneration in Italy, Germany, USA and United Kingdom (PO) (NCT01741532)
  • 01 Dec 2016 ApoPharma completes the phase II trial in Amyotrophic lateral sclerosis in France (PO) (NCT02164253)
  • 05 Aug 2016 Phase-II clinical trials in Parkinson's disease (Early-stage disease, Treatment-experienced) in USA (PO, Controlled-release) (NCT02728843)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top